What should the workflow be for a therapist and a psychiatric‑mental health nurse practitioner in an integrative collaborative medication‑assisted treatment opioid treatment program?

Workflow for Therapist and PMHNP in Integrative Collaborative MAT OTP Setting

The optimal workflow follows the collaborative care model (CCM) structure with clearly delineated roles: the PMHNP manages medication-assisted treatment (methadone/buprenorphine) and psychiatric medications, while the therapist functions as a behavioral health care manager providing measurement-based care, brief evidence-based psychotherapy, patient engagement, and care coordination—both working under psychiatric consultation for complex cases. 1, 2, 3

Core Team Structure and Roles

PMHNP Responsibilities

Medication Management:

• Prescribe and manage MOUD (methadone, buprenorphine, or naltrexone) following evidence-based protocols 1, 4
• For methadone: verify dosing with OTP, monitor for QTc prolongation with baseline and interval ECGs, consider split-dosing (6-8 hour intervals) for pain management 5
• For buprenorphine: prescribe maintenance doses, coordinate with therapist on patient adherence
• Manage co-occurring psychiatric medications (antidepressants, non-benzodiazepine anxiolytics) 2

Clinical Monitoring:

• Review Prescription Drug Monitoring Program (PDMP) data at initiation and every 1-3 months 6, 1
• Order and interpret urine drug screens before starting opioids and at least annually 1
• Calculate morphine milligram equivalents (MME) if prescribing additional opioids, keeping <50 MME/day 6
• Avoid concurrent benzodiazepine prescribing—if patient on benzodiazepines from another provider, coordinate taper (benzodiazepines first due to withdrawal risks) 7, 2

Assessment Schedule:

• Initial comprehensive evaluation with DSM-5 OUD criteria assessment 7, 2
• Return visits at 1-4 weeks after MOUD initiation 8
• Ongoing reassessment every 3 months minimum 1

Therapist (Behavioral Health Care Manager) Responsibilities

Patient Engagement and Retention:

• Create environment of disclosure and normalize OUD treatment 9
• Provide gentle but persistent outreach for missed appointments 9
• Offer human connection and encouragement, avoiding stigmatizing language 9
• Tailor treatment approaches to individual patient needs 9

Evidence-Based Psychotherapy:

• Deliver brief behavioral therapies (cognitive behavioral therapy, motivational enhancement therapy) for both OUD and co-occurring mental health conditions 7, 2
• Provide psychoeducation on OUD as chronic disease, MOUD mechanisms, overdose prevention 1
• Address psychosocial stressors, sleep issues, and contributing factors 8

Measurement-Based Care:

• Administer standardized assessments at each visit:
  • Days of opioid use (past month) 3
  • Mental health symptom scales (e.g., PHQ-9 for depression, GAD-7 for anxiety) 3
  • Functional status measures 8
• Track and document progress, sharing data with PMHNP for medication decisions

Care Coordination:

• Monitor medication adherence through patient self-report and coordination with pharmacy 9
• Facilitate communication between PMHNP, OTP (if methadone), and other providers 5, 10
• Connect patients to recovery support services, housing, employment resources 9
• Schedule and prepare patients for PMHNP appointments

Integrated Workflow Process

Initial Patient Entry (Week 1)

1. Therapist conducts intake screening:

   • DSM-5 OUD criteria assessment
   • Co-occurring mental health screening (depression, anxiety, PTSD)
   • Social determinants of health assessment
   • Treatment history and patient goals

2. PMHNP medical evaluation (within 1 week):

   • Medical history and physical exam focused on OUD complications
   • Review PDMP data 1
   • Baseline urine drug screen 1
   • ECG if considering methadone 5
   • Initiate MOUD with shared decision-making
   • Prescribe naloxone for overdose prevention 1

3. Collaborative treatment planning:

   • Joint meeting (or warm handoff) to establish unified treatment plan
   • Set realistic goals for substance use reduction and functional improvement 8, 1
   • Establish measurement schedule and crisis protocols

Ongoing Care (Weeks 2-12)

Weekly therapist contacts:

• Brief check-ins (15-30 minutes) for engagement and symptom monitoring
• Deliver structured brief therapy sessions (30-60 minutes) weekly or biweekly
• Administer measurement tools and track trends
• Identify early warning signs of relapse or medication non-adherence

PMHNP visits:

• Week 1-4: Weekly or biweekly for medication titration and safety monitoring 1
• Months 2-3: Every 2-4 weeks as patient stabilizes
• Review therapist's measurement data to inform medication adjustments
• Address medication side effects and drug interactions

Psychiatric consultation (as needed):

• Complex cases with treatment-resistant symptoms
• Polypharmacy concerns or significant medical comorbidities
• Consultation available to both PMHNP and therapist 3

Maintenance Phase (Month 4+)

Therapist contacts:

• Biweekly to monthly sessions depending on stability
• Continue measurement-based care at each contact
• Transition to relapse prevention and recovery maintenance focus
• Maintain engagement through flexible scheduling 11

PMHNP visits:

• Every 3 months minimum for stable patients 1
• Review benefits and harms of continued therapy
• Annual urine drug screening 1
• Quarterly PDMP review 1
• Coordinate any needed medication adjustments based on therapist feedback

Critical Communication Protocols

Daily/Weekly Team Huddles:

• Brief case reviews of high-risk patients
• Coordinate care plans for patients showing declining engagement
• Share measurement data trends requiring clinical attention

Formal Case Conferences (Monthly):

• Review all active patients systematically
• Psychiatric consultant participation for complex cases 3
• Adjust treatment intensity based on outcomes

Documentation Sharing:

• Shared electronic health record access for real-time care coordination
• Therapist documents measurement scores, session attendance, psychosocial updates
• PMHNP documents medication changes, lab results, medical concerns
• Both flag urgent issues for same-day communication

Common Pitfalls and Solutions

Pitfall 1: Fragmented care with poor communication

• Solution: Implement structured communication protocols (huddles, shared documentation) rather than ad hoc coordination 12, 3

Pitfall 2: Therapist scope creep into medication management

• Solution: Clear role delineation—therapist monitors and reports, PMHNP prescribes and adjusts 3

Pitfall 3: Dismissing patients for positive drug screens or missed appointments

• Solution: Use positive screens as engagement opportunities; persistent outreach is evidence-based practice 7, 9

Pitfall 4: Inadequate treatment of co-occurring mental health conditions

• Solution: Therapist provides integrated treatment for both OUD and psychiatric symptoms using measurement-based approach 3, 13

Pitfall 5: Prescribing benzodiazepines concurrently with MOUD

• Solution: PMHNP should avoid this combination; if patient on benzodiazepines, coordinate gradual taper while therapist provides CBT for anxiety 7, 2

Regulatory Coordination for OTP Settings

When methadone is dispensed through OTP:

• PMHNP obtains signed release for information exchange with OTP 5
• Verify methadone dose and timing with OTP before any additional opioid prescribing 10
• Notify OTP of hospitalizations, additional controlled substances prescribed 10
• For acute pain: continue methadone maintenance dose, add short-acting opioids separately 10
• Therapist coordinates with OTP counseling staff to avoid duplicative services while ensuring comprehensive behavioral support

This collaborative structure leverages the strengths of both disciplines while maintaining clear accountability, maximizes patient engagement through frequent therapeutic contact, and ensures medication safety through systematic PMHNP oversight—all supported by the strongest available evidence from collaborative care trials 3 and CDC guidelines 1, 2.